Breaking barriers for biomarker translation toward validation: Creating a new verification-class mass spectrometer with the Stellar mass spectrometer

Translational research strives to identify, verify, and validate biomarker candidates that can be used in clinical settings to collectively stratify biology. With the recent introduction of the Thermo Scientific^TM Orbitrap^TM Astral^TM mass spectrometer, the discovery phase of translational research can confidently identify 1000's of proteins and 100,000's of potential surrogate peptide markers. Taking the next step to determine which set of proteins and corresponding surrogate peptides are transitioned into the verification stage for targeted quantitative analysis has presented significant challenges using existing technology. With the recent introduction of the Thermo Scientific^TM Stellar^TM mass spectrometer, a new paradigm for targeted quantitation has been introduced to greatly expand the number of peptides quantified in a targeted quantitative method achieving higher LOQs using faster liquid chromatographic gradients.  This webinar will provide a detailed discussion on the new hardware and software innovations delivering the new performance that when coupled with low-flow UHPLC systems forms a power verification-class LC-MSⁿ solution. Translational research results will be presented on biomarker development studies for cancer, neurodegenerative disorders and amyloidosis. 

 

Learning Objectives